Background: Fragile X syndrome (FXS) is a single-gene disorder with a broad spectrum of involvement and a strong association with autism. Altered immune responses have been described in autism and there is potential that in children with FXS and autism, an abnormal immune response may play a role. Objectives: To delineate specific patterns of cytokine/chemokine profiles in individuals with FXS with and without autism and to compare them with typical developing controls. Methods: Age matched male subjects were recruited through the M.I.N.D. Institute and included: 19 typically developing controls, 64 subjects with FXS without autism and 40 subjects with FXS and autism. Autism diagnosis was confirmed with ADOS, ADI-R and DSM IV criteria. Plasma was isolated and cytokine and chemokine production was assessed by Luminex multiplex analysis. Results: Preliminary observations indicate significant differences in plasma protein levels of a number of cytokines, including IL-1a, and the chemokines; RANTES and IP-10, between the FXS group and the typical developing controls (p < 0.01). In addition, significant differences were observed between the FXS group with autism and the FXS without autism for IL-6, eotaxin, MCP-1 (p < 0.04). Conclusions: In this study, the first of its kind, we report a significantly altered cytokine profile in FXS. The characterization of an immunological profile in FXS with and without autism may help to elucidate if an abnormal immune response may play a role and help to identify mechanisms important in the etiology of autism both with and without FXS.
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Introduction
Fragile X syndrome (FXS) is a single-gene disorder with a broad spectrum of involvement including cognitive and behavioral impairments of varying degrees associated with distinct physical features. One behavioral phenotype of FXS is also characterized by autistic symptoms, including social and communication deficits, and stereotypic behavior. From the most recent studies, approximately 25-33% of children with FXS have autism (Kaufmann et al., 2004; Rogers et al., 2001 ) whereas pervasive developmental disorder-not otherwise specified (PDD-NOS) occurs in an additional 30%, and approximately 2-6% of children with autism have FXS (Estecio et al., 2002; Hagerman and Hagerman, 2002; Harris et al., 2008; Reddy, 2005; Wassink et al., 2001) .
Fragile X syndrome is nearly always caused by an expansion (>200) of a CGG trinucleotide repeat in the 5 0 untranslated region (5 0 UTR), followed by methylation and silencing of the Fragile X mental retardation 1 (FMR1) gene, with subsequent deficiency or absence of FMR1 protein (FMRP). It is the absence of FMRP, important for normal brain development that causes FXS (Irwin et al., 2000; Weiler and Greenough, 1999) . Since lack of FMRP leads to immature dendritic spines, it is thought that FMRP is involved in synaptogenesis, especially in the cerebral cortex, cerebellum and hippocampus, and, more specifically, in synaptic plasticity (Hagerman, 2006) .
Although the etiology of idiopathic autism without FXS is unknown, other causes of autism are associated with known gene defects including neuroligin, neurorexin or SHANK protein (Hagerman et al., 2008) . In addition, multiple genetic association studies have implicated genes that are relevant to the function of the immune system including human leukocyte antigens (HLA) complement C4, MET tyrosine kinase pathway, serine and threonine kinase C gene PRKCB1, macrophage inhibitory factor (MIF), Reelin and PTEN (reviewed in Enstrom et al. (2009) ). Moreover, altered
